Kathryn Guarini sold $340k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 400 shares at an average of $850.00, traded Sep 2, 2026, filed Sep 3, 2026.
Score components
- +15RoleDirector
- +15Trade size$340k at market
- +10Share of holdings soldSold 40% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001992352-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | MOption exercise Common Stock10b5-1 | +400 | $719.37 | $288k | 1,003 | 39 d ago |
| Sep 2, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $850.00 | $340k | 603 | 39 d ago |
| Sep 2, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 1,158 | 39 d ago |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $845k 1,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.